Reducing radiation doses for HPV-related throat cancer treatment
A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers
This study is looking at a new way to give less radiation to patients with HPV-related throat cancer, using special imaging to find out who can safely get a lower dose that might cause fewer side effects, like trouble swallowing, while still keeping the cancer under control.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10977310 on NIH RePORTER |
What this research studies
This research investigates a personalized approach to reduce radiation doses for patients with HPV-associated oropharyngeal cancer (OPC). By using advanced imaging techniques like PET/MRI, the study aims to identify patients who can safely receive a lower radiation dose of 30 Gy instead of the standard 70 Gy, which often leads to severe side effects. The goal is to maintain effective tumor control while minimizing treatment-related toxicity, particularly swallowing difficulties and mucositis. The research builds on promising initial findings from a pilot trial that showed high progression-free survival rates with reduced radiation doses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HPV-positive oropharyngeal cancer who show no signs of tumor hypoxia.
Not a fit: Patients with HPV-negative oropharyngeal cancer or those who do not meet the imaging criteria for hypoxia resolution may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the side effects of radiation therapy for patients with HPV-related throat cancer.
How similar studies have performed: Previous studies have shown promising results with reduced radiation doses in similar patient populations, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lee, Nancy Y — Sloan-Kettering Inst Can Research
- Study coordinator: Lee, Nancy Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.